September 20, 2002 |
British drug maker GlaxoSmithKline said Thursday that it settled litigation against Genentech Inc. that claimed its rival infringed patents covering monoclonal antibodies--cells grown in large fermentation tanks that can be programmed to attack disease. The companies did not disclose details of the confidential settlement, which ends two separate legal actions. As a result of the settlement, Glaxo dropped its appeal of a May 2001 jury verdict in favor of Genentech.
February 9, 2003 |
With a battle cry of "Tums down!" senior citizens groups have started a boycott of drug giant GlaxoSmithKline, after the company cut supplies to Canadian pharmacies that sell its drugs to Americans on the Internet at bargain prices. The seniors are taking aim at the British maker of Tums antacid, Aquafresh toothpaste, Contac cold remedy and dozens of common prescription medicines, calling Glaxo's decision "mean-spirited" and harmful to older people.
October 24, 2005 |
Drugstore shelves are brimming with shakes, herbs and other products to facilitate weight loss -- but the vast majority of them have not been shown to work. It's possible that a proven medication that helps modestly with weight loss may join their ranks next year. The pharmaceutical company GlaxoSmithKline has asked the Food and Drug Administration for permission to sell a low-dose version of its diet drug Xenical over the counter.
March 14, 2007 |
GlaxoSmithKline won U.S. approval Tuesday for a once-a-day breast cancer pill that the drug maker hopes will launch a new era for its oncology business. The Food and Drug Administration cleared the drug, called Tykerb, for patients with advanced breast cancer in combination with Roche Holding's oral chemotherapy drug, Xeloda, or capecitabine. It is the first of four cancer drugs that Glaxo hopes to have approved by 2010.
July 1, 2005 |
GlaxoSmithKline aims to launch five major vaccines over the next five years targeting markets that could reach $18 billion by 2010, Europe's biggest drug maker said Thursday. The company also plans to double manufacturing capacity in Dresden, Germany, for its flu shot Fluarix to 80 million doses a year by 2008 in order to supply the U.S. market. Vaccines have long been viewed as a low-growth, low-price business, but Glaxo says this is changing with the arrival of new technologies.
June 3, 2004 |
State Atty. Gen. Eliot Spitzer filed a lawsuit Wednesday charging one of the largest pharmaceutical companies in the world with hiding significant information about the benefits and risks of its antidepressant medicine Paxil for use in teenagers. The drug has been banned in England and other countries because of concern about side effects including violence and suicidal thoughts and behavior. In the United States, a strong federal warning was issued last June about its use by children.
August 20, 2003 |
GlaxoSmithKline and Bayer won Food and Drug Administration approval Tuesday for their Levitra impotence treatment, the first U.S. competitor for Pfizer Inc.'s $1.7-billion-a-year Viagra pill. The British and German drug makers estimate annual Levitra sales will reach $1.1 billion. The drug probably will sell at a slight discount to Viagra, which can cost more than $8 a tablet, company executives said in interviews.
August 27, 2004 |
GlaxoSmithKline agreed Thursday to release all data on the safety and effectiveness of its drugs to settle a lawsuit by New York's attorney general, who accused the pharmaceutical maker of withholding negative information about its antidepressant drug Paxil. Glaxo will put summaries of all its studies since December 2000 in a clinical trial registry on its website. The London-based company is the first major drug maker to agree to disclose all its studies. The company also will pay $2.
February 8, 2007 |
The Food and Drug Administration on Wednesday approved the first diet drug to be sold without a prescription. The drug is a lower-dose version of the prescription medicine Xenical and will become available to consumers this summer under the name alli. The pill will be marketed to people over 18 and will compete against nutritional supplements, which do not require FDA approval and the rigorous safety and efficacy testing that entails.
June 3, 2002 |
Bristol-Myers Squibb Co., a combination of two of the oldest names in American pharmaceuticals, has become a takeover target and the possible object of a multibillion-dollar bidding war in part because the drug industry faces unprecedented pressure to reduce prices at a time when the overall development of blockbuster drugs has slowed considerably. At the top of the list of suitors is GlaxoSmithKline, Europe's biggest drug maker and No. 2 in the world behind Pfizer Inc.